Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Capital Expenditures (2020 - 2025)

Maxcyte (MXCT) has disclosed Capital Expenditures for 6 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 184.83% to -$1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $176000.0, a 92.72% decrease, with the full-year FY2024 number at $1.7 million, down 55.38% from a year prior.
  • Capital Expenditures was -$1.2 million for Q3 2025 at Maxcyte, down from $584000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $17.7 million in Q4 2022 to a low of -$12.0 million in Q3 2022.
  • A 5-year average of $1.3 million and a median of $653000.0 in 2025 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 2349.69% in 2022; the steepest drop was 542.91% in 2022.
  • Maxcyte's Capital Expenditures stood at -$2.4 million in 2021, then surged by 830.97% to $17.7 million in 2022, then crashed by 94.82% to $915000.0 in 2023, then tumbled by 83.93% to $147000.0 in 2024, then crashed by 921.77% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Capital Expenditures are -$1.2 million (Q3 2025), $584000.0 (Q2 2025), and $653000.0 (Q1 2025).